Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials

Clinical Pharmacokinetics

Volumn 36, Issue 5, 1999, Pages 353-373

  Lamp, Kenneth C ^a,b   Freeman, Collin D ^b,c   Klutman, Neil E ^b,d   Lacy, Melinda K ^b,d  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b Kansas City Anti Infective Res G   (United States)

^c BAYER CORPORATION   (United States)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; OMEPRAZOLE; ORNIDAZOLE; PROTON PUMP INHIBITOR; SECNIDAZOLE; TINIDAZOLE;

ANAEROBIC INFECTION; ANTIBIOTIC RESISTANCE; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CRITICAL ILLNESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TISSUE LEVEL; ENTEROPATHY; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HEMODIALYSIS; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LIVER DYSFUNCTION; ORAL DRUG ADMINISTRATION; PEDIATRICS; POSTANTIBIOTIC EFFECT; PREGNANCY; PRIORITY JOURNAL; PROTOZOAL INFECTION; RECTAL DRUG ADMINISTRATION; REVIEW; SERUM BACTERICIDAL ACTIVITY; TOPICAL DRUG ADMINISTRATION; TRICHOMONIASIS;

ADULT; AGED; ANTI-INFECTIVE AGENTS; ANTITRICHOMONAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOSAGE FORMS; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; METRONIDAZOLE; MIDDLE AGED; NITROIMIDAZOLES; PREGNANCY; PROTOZOAN INFECTIONS; TISSUE DISTRIBUTION;

EID: 0032977537     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199936050-00004     Document Type: Review

References (130)

1. 1. Speck WT, Stein AB, Rosenkranz HS. Metronidazole bioassay. Antimicrob Agents Chemother 1976; 9: 260-1
2. 2. Durel P, Couture J, Bassoullet MT. The rapid detection of metronidazole in urine. Br J Vener Dis 1967; 43: 111-3
3. 3. Nilsson-Ehle I, Ursing B, Nilsson-Ehle P. Liquid chromatographic assay for metronidazole and tinidazole: pharmacokinetic and metabolic studies in human subjects. Antimicrob Agents Chemother 1981; 19: 754-60
4. 4. Wheeler LA, DeMeo M, Halula M, et al. Use of high-pressure liquid chromatography to determine plasma levels of metronidazole and metabolites after intravenous administration. Antimicrob Agents Chemother 1978; 13: 205-9
5. 5. Müller M. Mode of action of metronidazole on anaerobic bacteria and protozoa. Surgery 1983; 93: 165-71
6. 6. Edwards DI. Mechanism of antimicrobial action of metronidazole. J Antimicrob Chemother 1979; 5: 499-502
7. 7. Chrystal EJT, Koch RL, McLafferty MA, et al. Relationship between metronidazole metabolism and bactericidal activity. Antimicrob Agents Chemother 1980; 18: 566-73
8. 8. Britz ML, Wilkinson RG. Isolation and properties of metronidazole-resistant mutants of Bacteroides fragilis. Antimicrob Agents Chemother 1979; 16: 19-27
9. 9. Bergan T, Arnold E. Pharmacokinetics of metronidazole in healthy volunteers after tablets and suppositories. Chemotherapy 1980; 26: 231-41
10. 10. Ralph ED, Clarke JT, Libke RD, et al. Pharmacokinetics of metronidazole as determined by bioassay. Antimicrob Agents Chemother 1974; 6: 691-6
11. 11. Jensen JC, Gugler R. Single and multiple-dose metronidazole kinetics. Clin Pharmacol Ther 1983; 34: 481-7
12. 12. Houghton GW, Smith J, Thome PS, et al. The pharmacokinetics of oral and intravenous metronidazole in man. J Antimicrob Chemother 1979; 5: 621-3
13. 13. Houghton GW, Hundt HKL, Muller FO, et al. A comparison of the pharmacokinetics of metronidazole in man after oral administration of single doses of benzoylmetronidazole and metronidazole. Br J Clin Pharmacol 1982; 14: 201-6
14. 14. Fredricsson B, Hagström B, Nord CE, et al. Systemic concentrations of metronidazole and its main metabolites after intravenous oral and vaginal administration. Gynecol Obstet Invest 1987; 24: 200-7
15. 15. Loft S, Døssing M, Poulsen, HE, et al. Influence of dose and route of administration on disposition of metronidazole and its major metabolites. Eur J Clin Pharmacol 1986; 30: 467-73
16. 16. Houghton GW, Thorne PS, Smith J, et al. Comparison of pharmacokinetics of metronidazole in healthy female volunteers following either a single oral or intravenous dose. Br J Clin Pharmatol 1979; 8: 337-41
17. 17. Mattila J, Männistö PT, Mäntylä R, et al. Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrob Agents Chemother 1983; 23: 721-5
18. 18. Cunningham FE, Kraus DM, Brubaker L, et al. Pharmacokinetics of intravaginal metronidazole gel. J Clin Pharmacol 1994; 34: 1060-5
19. 19. Alper MM, Barwin N, McLean WM, et al. Systemic absorption of metronidazole by the vaginal route. Obstet Gynecol 1985; 65: 781-4
20. 20. Daneshmend TK, Homeida M, Kaye CM, et al. Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis. Gut 1982; 23: 807-13
21. 21. Schwartz DE, Jeunet F. Comparative pharmacokinetic studies of ornidazole and metronidazole in man. Chemotherapy 1976; 22: 19-29
22. 22. Bergan T, Leinebø O, Blom-Hagen T, et al. Pharmacokinetics and bioavailability of metronidazole after tablets, suppositories and intravenous administration. Scand J Gastroenterol 1984; 19 Suppl. 91: 45-60
23. 23. Amon I, Amon K, Hüller H. Pharmacokinetics and therapeutic efficacy of metronidazole at different dosages. Int J Clin Pharmacol 1978; 16: 384-6
24. 24. Lau AH, Emmons K, Seligsohn R. Pharmacokinetics of intravenous metronidazole at different dosages in healthy subjects. Int J Clin Pharmacol Ther Toxicol 1991; 29: 386-90
25. 25. Søreide O, Leinebø O, Bergan T, et al. Comparative pharmacokinetics of metronidazole and tinidazole used as single dose prophylactic agents. Scand J Gastroenterol 1984; Suppl 90: 97-106
26. 26. Solhaug JH, Bergan T, Leinebø, et al. The pharmacokinetics of one single perioperative dose of metronidazole or tinidazole. Scand J Gastroenterol 1984; Suppl. 90: 89-96
27. 27. Eradiri O, Jamali F, Thomson ABR. Steady-state pharmacokinetics of metronidazole in Crohn's disease. Biopharm Drug Dispos 1987; 8: 249-59
28. 28. Mattie H, Dijkmans AC, van Gulpen C. The pharmacokinetics of metronidazole and tinidazole in patients with mixed aerobic-anaerobic infections. J Antimicrob Chemother 1982; 10 Suppl. A: 59-64
29. 29. Wood BA, Monro AM. Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses. Br J Vener Dis 1975; 51: 51-3
30. 30. Amon I, Amon K, Franke G, et al. Pharmacokinetics of metronidazole in pregnant women. Chemotherapy 1981; 27: 73-9
31. 31. Anon. An evaluation of metronidazole in the prophylaxis and treatment of anaerobic infections in surgical patients. J Antimicrob Chemother 1975; 1: 393-401
32. 32. Houghton GW, Thorne PS, Smith J, et al. Plasma metronidazole concentrations after suppository administration. In: Phillips R, Collier J, eds. Metronidazole: proceedings of the second international symposium on anaerobic infections. Geneva, 1979 April. Royal Society of Medicine, London/Grune and Stratton, New York. New York: Academic Press, 1979: 41-4
33. 33. Aronson IK, Rumsfield JA, West DP, et al. Evaluation of topical metronidazole gel in acne rosacea. Drug Intell Clin Pharm 1987; 21: 346-51
34. 34. Schmadel LK, McEvoy GK. Topical metronidazole: a new therapy for rosacea. Clin Pharm 1990; 9: 94-101
35. 35. Warner JF, Perkins RL, Cordero L. Metronidazole therapy of anaerobic bacteremia, meningitis, and brain abscess. Arch Intern Med 1979; 139: 167-9
36. 36. O'Grady LK, Ralph ED. Anaerobic meningitis and bacteremia caused by Fusobacterium species. Am J Dis Child 1976; 130: 871-3
37. 37. Davies AH. Metronidazole in human infections with syphilis. Br J Vener Dis 1967; 43: 197-200
38. 38. Visser AA, Hundt HKL. The pharmacokinetics of a single intravenous dose of metronidazole in pregnant patients. J Antimicrob Chemother 1984; 13: 279-83
39. 39. Templeton R. Metabolism and pharmacokinetics of metronidazole: a review. In: Finegold SM, McFadzcan JA, Roe RJ, editors. Proceedings of the International Metronidazole Conference; 1976 May; Montreal, Quebec, Canada. Amsterdam: Excerpta Medica, 1977: 28-48
40. 40. Elder MG, Kane JL. The pelvic tissue levels achieved by metronidazole after single or multiple dosing: oral and rectal. In: Phillips R, Collier J, editors. Metronidazole: proceedings of the second international symposium on anaerobic infections. 1979 Apr; Geneva. Royal Society of Medicine, London. New York: Academic Press, 1979: 55-8
41. 41. Berger SA, Kupfermine M, Lessing JB, et al. Penetration of clindamycin, cefoxitin, and metronidazole into pelvic peritoneal fluid of women undergoing diagnostic laparoscopy. Antimicrob Agents Chemother 1990; 34: 376-7
42. 42. Büchler M, Malfertheiner P, Friess H, et al. The penetration of antibiotics into human pancreas. Infection 1989; 17: 26-31
43. 43. Bassi C, Pederzoli P, Vesentini S, et al. Behavior of antibiotics during human necrotizing pancreatitis. Antimicrob Agents Chemother 1994; 38: 830-6
44. 44. Kling PA, Burman LG. Serum and tissue pharmacokinetics of intravenous metronidazole in surgical patients. Acta Chir Scand 1989; 155: 347-50
45. 45. Martin C, Sastre H, Mallet MN, et al. Pharmacokinetics and tissue penetration of a single 1,000-milligram, intravenous dose of metronidazole for antibiotic prophylaxis of colorectal surgery. Antimicrob Agents Chemother 1991; 35: 2602-5
46. 46. Rood JP, Collier J. Metronidazole levels in alveolar bone. In: Phillips R, Collier J, eds. Metronidazole: proceedings of the second international symposium on anaerobic infections. Geneva, 1979 April. Royal Society of Medicine, London/Grune and Stratton, New York. New York: Academic Press, 1079: 45-7
47. 47. Taylor Jr JA, Migliardi JR, Schach von Wittenau M. Tinidazole and metronidazole pharmacokinetics in man and mouse. Antimicrob Agents Chemother 1969: 267-70
48. 48. Jager Roman E, Doyle PE, Baird-Lambert J, et al. Pharmacokinetics and tissue distribution of metronidazole in the newborn infant. J Pediatr 1982; 100: 651-4
49. 49. Lau AH, Lam NP, Piscitelli SC. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 1992; 23: 328-64
50. 50. Amon I, Amon K, Scharp H, et al. Disposition kinetics of metronidazole in children. Eur J Clin Pharmacol 1983; 24: 113-9
51. 51. Ti TY, Lee HS, Khoo YM. Disposition of intravenous metronidazole in Asian surgical patients. Antimicrob Agents Chemother 1996; 40: 2248-51
52. 52. Hand WL, King-Thompson N, Holman JW. Entry of roxithromycin (RU 965), imipenem, cefotaxime, trimethoprim, and metronidazole into human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1987; 31: 1553-7
53. 53. Soriano F, Aguado JM, Tornero J, et al. Bacteroids fragilis meningitis successfully treated with metronidazole after a previous failure with thiamphenicol. J Clin Microbiol 1986; 24: 472-3
54. 54. Feldman WE. Bacteroides fragilis ventriculitis and meningitis. Am J Dis Child 1976; 84: 50-1
55. 55. George KH, Bint AJ. Treatment of a brain abscess due to Bacteroides fragilis with metronidazole. J Antimicrob Chemother 1976; 2: 101-2
56. 56. Ingham HR, Selkon JB, Roxby CM. Bacteriological study of otogenic cerebral abscesses: chemotherapeutic role of metronidazole. BMJ 1977; 2: 991-3
57. 57. Bergan T, Solhaug JH, Søreide O, et al. Comparative pharmacokinetics of metronidazole and tinidazole and their tissue penetration. Scand J Gastroenterol 1985; 20: 945-50
58. 58. Van Oosten MAC, Notten FJW, Mikx FHM. Metronidazole concentrations in human plasma, saliva, and gingival crevice fluid after a single dose. J Dent Res 1986; 65: 1420-3
59. 59. O'Keefe JP, Troc KA, Thompson KA. Activity of metronidazole and its hydroxy and acid metabolites against clinical isolates of anaerobic bacteria. Antimicrob Agents Chemother 1982; 22: 426-30
60. 60. Pavicie MJAMP, van Winkelhoff AJ, de Graaff J. Synergistic effects between amoxicillin, metronidazole, and the hydroxy-metabolite of metronidazole against Actinobacillus actinomycetemcomitans. Antimicrob Agents Chemother 1991; 35: 961-6
61. 61. Andersson KE. Pharmacokinetics of nitroimidazoles: spectrum of adverse reactions. Scand J Infect Dis 1981; Suppl. 26: 60-7
62. 62. Ralph ED, Kirby WMM. Bioassay of metronidazole with either anaerobic or aerobic incubation. J Infect Dis 1975; 132: 587-91
63. 63. Ralph ED. Clinical pharmacokinetics of metronidazole. Clin Pharmacokinet 1983; 8: 43-62
64. 64. Loft S, Poulsen HE, Sonne J, Døssing M. Metronidazole clearance: a one-sample method and influencing factors. Clin Pharmacol Ther 1988; 43: 420-8
65. 65. Thiercelin JF, Diquet B, Levesque C, et al. Metronidazole kinetics and bioavailability in patients undergoing gastrointestinal surgery. Clin Pharmacol Ther 1984; 35: 510-9
66. 66. Bergan T, Aase, Leinbo O, et al. Pharmacokinetics of metronidazole and its major metabolite after a high intravenous dose. Scand J Gastroenterol 1984; 19 Suppl. 91: 113-23
67. 67. Somogyi AA, Kong CB, Gurr FW, et al. Metronidazole pharmacokinetics in patients with acute renal failure. J Antimicrob Chemother 1984; 13: 183-9
68. 68. Houghton GW, Dennis MJ, Gabriel R. Pharmacokinetics of metronidazole in patients with varying degrees of renal failure. Br J Clin Pharm 1985; 19: 203-9
69. 69. Bergan T, Thorsteinsson SB. Pharmacokinetics of metronidazole and its metabolites in reduced renal function. Chemotherapy 1986; 32: 305-18
70. 70. Kreeft JH, Ogilvie RI, Dufresne LR. Metronidazole kinetics in dialysis patients. Surgery 1983; 93: 149-53
71. 71. Lau AH, Chang CW, Sabatini S. Hemodialysis clearance of metronidazole and its metabolites. Antimicrob Agents Chemother 1986; 29: 235-8
72. 72. Cassey JG, Clark DA, Merrick P, et al. Pharmacokinetics of metronidazole in patients undergoing peritoneal dialysis. Antimicrob Agents Chemother 1983; 24: 950-1
73. 73. Guay DR, Meatherall RC, Baxter H, et al. Pharmacokinetics of metronidazole in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1984; 25: 306-10
74. 74. Loft S, Sonne J, Døssing M, et al. Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol 1987; 22: 117-23
75. 75. Lau AH, Evans R, Chang C-W, et al. Pharmacokinetics of metronidazole in patients with alcoholic liver disease. Antimicrob Agents Chemother 1987; 31: 1662-4
76. 76. Muscará MN, Pedrazzoli Jr J, Miranda EL, et al. Plasma hydroxy-metronidazole metronidazole ratio in patients with liver disease and in healthy volunteers. Br J Clin Pharmacol 1995; 40: 477-80
77. 77. Lares-Asseff I, Cravioto J, Santiago P, et al. Pharmacokinetics of metronidazole in severely malnourished and nutritionally rehabilitated children. Clin Pharmacol Ther 1992; 51: 42-50
78. 78. Shaffer JL, Kershaw A, Houston JB. Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease. Br J Clin Pharmacol 1986; 21: 431-5
79. 79. Bergan T, Bjerke Per EM, Fausa O. Pharmacokineties of metronidazole in patients with enteric disease compared to normal volunteers. Chemotherapy 1981; 27: 233-8
80. 80. Plaisance KI, Quintiliani R, Nightingale CH. The pharmacokinetics of metronidazole and its metabolites in critically ill patients. J Antimicrob Chemother 1998; 21: 195-200
81. 81. Selkon JB. The need for and choice of chemotherapy for anaerobic infections. Scand J Infect Dis 1981; 26 Suppl.: 19-23
82. 82. Spangler SK, Jacobs MR, Appelbaum PC. Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxilin, piperacillin, and piperacillin/tazobactam against six anaerobes. J Antimicrob Chemother 1997; 39 Suppl. B: 23-7
83. 83. Werk R, Schneider L. Ciprofloxacin in combination with melronidazole. Infection 1988; 16: 257-60
84. 84. Bartlett JG, Louie TJ, Gorbach SL, et al. Therapeutic efficacy of 29 antimicrobial regimens in experimental intraabdominal sepsis. Rev Infect Dis 1981; 3: 535-42
85. 85. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1991; 74 Suppl. 74: 63-70
86. 86. Nix DE, Tyrrell R, Müller M. Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis. Antimicrob Agents Chemother 1995; 39: 1848-52
87. 87. Estes L. Review of pharmacokinetics and pharmacodynamics of antimicrobial agents. Mayo Clin Proc 1998; 73: 1114-22
88. 88. Van der Auwera P, Van Laethem Y, Defresne N, et al. Comparative serum bactericidal activity against test anaerobes in volunteers receiving imipenem, clindamycin, latamoxef, and metronidazole. J Antimicrob Chemother 1987; 19: 205-10
89. 89. Depperman KM, Boeckh M, Grineisen S, et al. Brief report: combination effects of ciprofloxacin, clindamycin, and metronidazole intravenously in volunteers. Am J Med 1989; 87 Suppl. 5A: 46S-8S
90. 90. Boeckh M, Lode H, Deppermann KM, et al. Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. Antimicrob Agents Chemother 1990; 34: 2407-14
91. 91. Pefanis A, Thauvin-Elipoulos C, Holden J, et al. Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses. Antimicrob Agents Chemother 1994; 38: 252-5
92. 92. Kowatsky SF, Echols RM, McCormick EM. Comparative serum bactericidal activity of ceftizoxime/metronidazole, ceftizoxime, clindamycin, and imipenem against obligate anaerobic bacteria. J Antimicrob Chemother 1990; 25: 767-75
93. 93. Freeman CD, Nightingale CH, Nicolau DH, et al. Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam. Pharmacotherapy 1994; 14: 185-90
94. 94. Freeman CD, Nightingale CH, Nicolau DP, et al. Serum bactericidal activity of ceftriaxone plus metronidazole against common intra-abdominal pathogens. Am J Hosp Pharm 1994; 51: 1782-7
95. 95. Goddard AF, Jessa MJ, Barrett DA, et al. Effect of orneprazole on the distribution of metronidazole, amocillin, and clarithromycin in human gastric juice. Gastroenterol 1996; 111: 358-67
96. 96. Jessa MJ, Goddard AF, Barrett DA, et al. The effect of omeprazole on the pharmacokinetics of metronidazole and hydroxymetronidazole in human plasma, saliva and gastric juice. Br J Clin Pharm 1997; 44: 245-53
97. 97. Goldman P. The development of 5-nitroimidazoles for the treatment and prophylaxis of anaerobic bacterial infections. J Antimicrob Chemother 1982; 10: 23-42
98. 98. Charuel C, Nachbaur J, Monro AM, et al. The pharmacokinetics of intravenous tinidazole in man. J Antimicrob Chemother 1981; 8: 343-4
99. 99. Robson RA, Bailey RR, Sharman JR. Tinidazole pharmacokinetics in severe renal failure. Clin Pharmacokinet 1984; 9: 88-94
100. 100. Evaldson GR, Lindgren S, Nord CE, et al. Tinidazole milk excretion and pharmacokinetics in lactating women. Br J Clin Pharmacol 1985; 19: 503-7
101. 14C-tinidazole in humans. J Antimicrob Chemother 1986; 17: 801-9
102. 102. Vinge E, Anderson KE, Ando G, et al. Biological availability and pharmacokinetics of tinidazole after single and multiple dose. Scand J Infect Dis 1983; 15 (4): 391-7
103. 103. Klimowicz A, Nowak A, Bielecka-Grzela S. Penetration of tinidazole into blister fluid following its oral administration. Eur J Clin Pharmacol 1992; 43: 523-6
104. 104. Wood BA, Faulkner JK, Munro AM. The pharmacokinetics, metabolism, and tissue distribution of tinidazole. J Antimicrob Chemother 1982; 10 (A): 43-57
105. 105. Vittanen J, Auvinen O, Tunturi T. Serum and tissue tinidazole concentrations after intravenous infusion. Chemother 1983; 29: 13-7
106. 106. Karhunen M. Placental transfer of metronidazole and tinidazole in early human pregnancy after a single infusion. Br J Clin Pharmacol 1984; 18: 254-7
107. 107. Carmine AA, Brogden RN, Heel RC, et al. Tinidazole in anaerobic infections. A review of its antibacterial activity, pharmacological properties and therapeutic efficacy. Drugs 1982; 24: 85-117
108. 108. Jokipii AMM, Myllyla VV, Hokkanen H, et al. Penetration of the blood brain barrier by metronidazole and tinidazole. J Antimicrob Chemother 1977; 3: 239-45
109. 109. Packard RS. Tinidazole: a review of clinical experience in anaerobic infections. J Antimicrob Chemother 1982; 10 (A): 65-72
110. 110. Jokipii L, Jokipii AMM. Treatment of giardiasis: comparative evaluation of ornidazole and tinidazole as a single dose. Gastroenterology 1982; 83: 399-404
111. 111. Martin C, Bruguerolle B, Mallet MN, et al. Pharmacokinetics and tissue penetration of a single dose of ornidazole (1,000 milligrams intravenously) for antibiotic prophylaxis in colorectal surgery. Antimicrob Agents Chemother 1990; 34: 1921-4
112. 112. Rossignol JF, Maisonneuve H, Cho YW. Nitroimidazoles in the treatment of trichomoniasis, giardiasis, and amebiasis. Int J Clin Pharmacol Ther Toxitol 1984; 22: 63-72
113. 113. Heizmann P, Geschke R, Zinapold K. Determination of ornidazole and its main metabolites in biological fluids. J Chromatography 1990; 534: 233-40
114. 114. Matheson I, Johannessen KH, Bjorkvoll B. Plasma levels after a single oral dose of 1.5 g ornidazole. Br J Vener Dis 1977; 53: 236-9
115. 115. Taburet AM, Delion F, Attali P, et al. Pharmacokinetics of or nidazole in patients with severe liver cirrhosis. Clin Pharmacol Ther 1986; 4: 359-64
116. 116. Turcant A, Granry JC, Allain P, et al. Pharmacokinetics of ornidazole in neonates and infants after a single intravenous infusion. Eur J Clin Pharmacol 1987; 32: 111-3
117. 117. Horber FF, Maurer O, Probst PJ, et al. High haemodialysis clearance of ornidazole in the presence of a negligible renal clearance. Eur J Clin Pharmacol 1989; 36: 389-93
118. 118. Merdjan H, Baumelou A, Diquet B, et al. Pharmacokinetics of ornidazole in patients with renal insufficiency: influence of haemodialysis and peritoneal dialysis. Br J Clin Pharmacol 1985; 19: 211-7
119. 119. Taburet AM, Attali P, Bourget P, et al. Pharmacokinetics of ornidazole in patients with acute viral hepatitis, alcoholic cirrhosis, and extrahepatic cholestasis. Clin Pharmacol Ther 1989; 45: 373-9
120. 120. Steib A, Jacoberger B, Von Bandel M et al. Concentrations in plasma and tissue penetration nf ceftriaxone and ornidazole during liver transplantation. Antimicrob Agents Chemother 1993; 37: 1873-6
121. 121. Bourget P, Dechelette N, Fernandez H, et al. Disposition of ornidazole and its metabolites during pregnancy. J Antimicrob Chemother 1995; 35: 691-6
122. 122. Jokipii AMM, Jokipii L. Metronidazole, tinidazoec, ornidazole and anaerobic infections of the middle car, maxillary sinus and central nervous system. Scand J Infect Dis 1981; Suppl. 26: 123-9
123. 123. Schwartz DE, Jordan JC, Vetter W, et al. Metabolic studies of ornidazole in the rat, in the dog and in man. Xenobiotica 1979; 9: 571-81
124. 124. Jokipii L, Jokipii AMM. Comparative evaluation of the 2-methyl-5-nitroimidazole compounds dimetridazole, metroni dazole, secnidazole, ornidazole, carnidazole, and panidazole against Bacteroides fragilis and other bacteria of the Bacteroides fragilis group. Antimicrob Agents Chemother 1985; 28: 561-4
125. 125. Olsson-Liljequist B, Nord CE. In vitro susceptibility of anaerobic bacteria to nitroimidazoles. Scand J Infect Dis 1981; Suppl 26: 42-5
126. 126. Cedillo-Rivera R, Munoz O. In vitro susceptibility of Giardia lamblia to albendazole, mebendazole and other chemotherapeutic agents. J Med Microbiol 1992; 37: 221-4
127. 127. Wust J. Susceptibility of anaerobic bacteria to metronidazole, ornidazole, and tinidazole and routine susceptibility testing by standardized methods. Antimicrob Agents Chemother 1977; 11: 631-7
128. 128. Gillis JC, Wiseman LR, Secnidazole; a review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs 1996; 51: 621-38
129. 129. Tenebaum H, Cuisinier FJG, Le Liboux A, et al. Secnidaozle conentrations in plasma and crevicular fluid after a single oral dose. J Clin Periodontol 1993; 20: 505-8
130. 130. Maurice M, Pichard L, Daujat M, et al. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 1992; 6: 752-8